SCHEMBL13250033

SCHEMBL13250033

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
C5AR1 P21730 1/20 0.39
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
ATM Q13315 1/20 0.37
DTYMK P23919 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
P2RX3 P56373 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
GLS O94925 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
MAPK1 P28482 1/20 0.35
MTOR P42345 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249769 0.91 PARP1 (0.48) PARP1TNKS2PARP2P2RX3MAPK1
SCHEMBL13328836 0.91 MAPT (0.43) PARP1TNKS2PARP2C5AR1P2RX3
SCHEMBL13250092 0.86 PARP1 (0.44) PARP1TNKS2PARP2P2RX3MAPK1
SCHEMBL13249998 0.86 PARP1 (0.44) PARP1TNKS2PARP2P2RX3MKNK1
SCHEMBL13328818 0.86 PRLHR (0.42) MAPT
SCHEMBL13250063 0.85 PARP1 (0.40) PARP1TNKS2PARP2ALOX15TSHR
SCHEMBL13249990 0.84 PARP1 (0.43) PARP1TNKS2PARP2P2RX3GPR119
SCHEMBL13250039 0.84 GAA (0.37) TSHRMAPK1MAPT
SCHEMBL13249886 0.84 HPGD (0.41) PARP1TNKS2PARP2P2RX3GPR119
SCHEMBL13250459 0.84 PARP1 (0.42) PARP1TNKS2PARP2P2RX3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed
WO-2008130581-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 PARP1 995/4885TNKS2 2045/4885PARP2 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.